What I like most about this Long Term Play:
This may be the First Natural BioPharma Play use to TREAT some serious conditions. TREAT is Key, cannot make that claim with FDA approval. Hugh IN My Opinion.
Buy-Out well what ever for what penny or two. Hope not.
From HBRM's Plans
Herborium uses a Phased approach for product introduction to the market to capitalize on the existing and emerging opportunities of the Healthcare sector.
Phase I:
Immediate entry to the US market under DSHEA 94. Market differentiation utilizing historical clinical data, trade secret protection of proprietary formulas, and premium pricing with initial brand recognition.
Phase II
: Perform confirmatory clinical studies in the US under IND's defined by the new FDA Guidance relating to Botanical Drugs; market penetration and unique market positioning as clinically tested Botanical Therapeutics; improve intellectual property protection and premium pricing; prepare for EU market presence as a licensed product.
Phase III
Herborium's model has been further strengthened by it's unique strategy for selecting therapeutic candidates. The Company's products address healthcare problems that are not satisfactorily met by conventional ethical pharmaceuticals and therefore satisfy niche market demands resulting from the gap between consumer's healthcare needs and currently available treatment options.
. Selected Botanical Therapeutics qualified for pharmaceutical development by clinical and market cost benefit analysis; proceed to FDA Phase II/III clinical studies whose results will, provide the basis for making clinical claims key to the advertising campaign and removing FDA disclaimers. Successful completion of clinical development enables possible licensing to Big Pharma.
Some Points from the CHRI PR.
The research initiative is focused on optimizing yields from raw Gastrodia and to find new potential uses of Gastrodia using deep processing.
CHRI recently signed a 3 year exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan. The quality of Gastrodia under this supply agreement is expected to meet the latest formal TCM pharmaceutical standard and gives CHRI continued leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of pharmaceutical grade Gastrodia (also known as Tianma).
What is Gastrodia
Gastrodia is a genus of achlorophyllous orchid with about 40 species. It is a traditional Chinese herb, Tian Ma (Chinese: ??), and is commonly used in China to treat hypertension, improve circulation and resolve headaches. It appears as an allergy herb in Allerphase and is largely responsible for the formula's ability to relieve brain fog- one of the main symptoms of allergies. Modern research suggests that gastrodia aids in improving memory by promoting blood flow to the brain and enhances the ability of other herbs to quickly reach inflamed brain tissues to reduce inflammation, control pain, and reduce mental confusion. Gastrodia root has been shown to exert novel pain relief and inflammatory-mediating activities, as well as in vivo and in vitro inhibitory activity on nitric oxide (NO) production
Earning Guidance without HBRM
China Health Resource Reports on Preliminary Record Fourth Quarter and Year-End 2011 Results; Announces 2012 Earnings Guidance
2011 record breaking sales and earnings well above Company's expectations
-- Revenues expected to increase by $24.7 million or 241% year-over-year to $34.9 million
-- Net Income expected to total to $6.8 million, or $0.038 per share for 2011 an increase of approx 150% (total shares over 176 million)
-- Company announces earnings guidance for 2012 and establishes a range between $0.06 and $0.065 per share
News 
Market Data 
Discover 
AI
